Subscribe

Dong-A ST Co., Ltd. (170900.KS)

KRW35,900.00 +1,150.00 (+3.31%)
KR KSC Healthcare Drug Manufacturers - Specialty & Generic
Address 64 Cheonhodaero
Seoul, KR
CEO Jae-Hun Jung
Website donga-st.com
IPO 2013-04-05
ISIN KR7170900005

Explore sections of this company profile

Description

Dong-A ST Co., Ltd. is a global enterprise focused on the research, development, production, and commercialization of a broad spectrum of pharmaceutical products and medical devices. The company's diverse portfolio of ethical drugs targets various medical conditions, including tuberculosis (with treatments like Closerin and Terizidone), neutropenia in chemotherapy patients (such as Dulastin and Leucostim), and anemia stemming from chronic renal failure (Eporon). Its robust oncology offerings feature Gemcit for cancers affecting the lung, pancreas, breast, bladder, and ovaries; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; and Monotaxel, indicated for breast, prostate, head, neck, and gastric adenocarcinoma, among others. Additionally, Dong-A ST provides solutions for infertility and anovulation (Gonadopin), growth hormone deficiency and idiopathic short stature (Growtropin II), functional dyspepsia (Motilitone), gastritis (Stillen), diabetes (Suganon), and erectile dysfunction (Zydena). The company also actively participates in pharmaceutical licensing, encompassing both the acquisition and out-licensing of drugs. Its medical device segment includes advanced technological equipment, customized products, and specialized artificial cardiac circuit sets essential for complex open-heart surgeries. Dong-A ST Co., Ltd. was established in 1932 and is headquartered in Seoul, South Korea.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
KRW35,900.00 +1,150.00 (+3.31%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
19.0K
Beta
0.38
Float Shares
5.09M
Free Float %
52.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-2.32% -6.76% -9.71% -23.52% -14.57% -22.48% -4.53% -13.66% -43.06% -63.19% -68.82%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
35,900.00
Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 3 0
Buy 2 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
1.11
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +15.9% ★ Q1'26: +11.8% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    -2,000.7% Q1'26: +195.9% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    -3.8% Q1'26: -9.8% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +0.1% Q1'26: +3.8% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +0.1% Q1'26: +2.6% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +10.2% Q1'26: +10.5% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    16.06× Q1'26: 7.85× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.46) × ERP
WACC = 42% × Ke + 58% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 35,900.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
3 Rev. Ana.
2 EPS Ana. 		Dec 2027
4 Rev. Ana.
2 EPS Ana. 		Dec 2028
2 Rev. Ana.
1 EPS Ana.
Revenue
581.00B
est: 575.60B (+0.9%)
560.54B
est: 610.13B (-8.1%)
555.03B
est: 552.86B (+0.4%)
567.43B
est: 573.71B (-1.1%)
612.31B
est: 607.18B (+0.8%)
586.73B
est: 600.80B (-2.3%)
593.23B
est: 592.03B (+0.2%)
635.39B
est: 634.88B (+0.1%)
663.98B
est: 608.37B (+9.1%)
697.87B
est: 648.09B (+7.7%)
808.79B
est: 731.10B (+10.6%)
837.06B
817.47B – 856.58B
+14.5% YoY
903.56B
862.38B – 944.59B
+7.9% YoY
964.70B
942.12B – 987.20B
+6.8% YoY
EBITDA
77.84B
est: 39.90B (+95.1%)
33.66B
est: 42.30B (-20.4%)
44.66B
est: 38.33B (+16.5%)
59.47B
est: 39.77B (+49.5%)
77.05B
est: 42.09B (+83.0%)
58.45B
est: 41.65B (+40.3%)
35.51B
est: 41.04B (-13.5%)
49.40B
est: 44.01B (+12.2%)
45.07B
est: 42.18B (+6.9%)
28.99B
est: 37.38B (-22.4%)
33.45B
est: 42.17B (-20.7%)
48.28B
47.15B – 49.40B
+14.5% YoY
52.11B
49.74B – 54.48B
+7.9% YoY
55.64B
54.34B – 56.94B
+6.8% YoY
EBIT
77.86B
est: 18.96B (+310.6%)
12.54B
est: 20.10B (-37.6%)
219.66M
est: 18.21B (-98.8%)
22.92B
est: 18.90B (+21.3%)
96.56B
est: 20.00B (+382.7%)
38.48B
est: 19.79B (+94.4%)
17.71B
est: 19.50B (-9.2%)
28.55B
est: 20.92B (+36.5%)
18.73B
est: 20.04B (-6.6%)
-153.44M
est: 12.95B (-101.2%)
618.35M
est: 14.61B (-95.8%)
16.72B
16.33B – 17.11B
+14.5% YoY
18.05B
17.23B – 18.87B
+7.9% YoY
19.28B
18.82B – 19.72B
+6.8% YoY
Net Income
48.56B
est: 43.28B (+12.2%)
10.63B
est: 22.51B (-52.8%)
-5.40B
est: 7.90B (-168.3%)
8.01B
est: 35.68B (-77.6%)
70.91B
est: 53.43B (+32.7%)
27.10B
est: 29.17B (-7.1%)
12.82B
est: 17.15B (-25.3%)
13.55B
est: 31.86B (-57.5%)
11.12B
est: 22.37B (-50.3%)
-1.22B
est: 15.46B (-107.9%)
-28.59B
est: 7.29B (-492.4%)
23.85B
23.12B – 24.57B
+227.2% YoY
33.06B
20.10B – 46.02B
+38.6% YoY
36.45B
35.34B – 37.55B
+10.2% YoY
SGA
100.99B
est: 85.40B (+18.3%)
98.82B
est: 90.52B (+9.2%)
92.57B
est: 82.02B (+12.9%)
90.59B
est: 85.12B (+6.4%)
85.66B
est: 90.08B (-4.9%)
78.40B
est: 89.13B (-12.0%)
97.06B
est: 87.83B (+10.5%)
100.97B
est: 94.19B (+7.2%)
95.20B
est: 90.26B (+5.5%)
99.27B
est: 95.78B (+3.6%)
105.78B
est: 108.05B (-2.1%)
123.71B
120.82B – 126.60B
+14.5% YoY
133.54B
127.45B – 139.60B
+7.9% YoY
142.58B
139.24B – 145.90B
+6.8% YoY
EPS
6,070.59
est: 5,003.63 (+21.3%)
1,243.14
est: 2,602.04 (-52.2%)
-626.47
est: 913.62 (-168.6%)
930.39
est: 4,125.60 (-77.4%)
8,077.26
est: 6,178.07 (+30.7%)
3,087.14
est: 3,372.95 (-8.5%)
1,459.74
est: 1,982.65 (-26.4%)
1,543.95
est: 3,683.65 (-58.1%)
1,474.18
est: 2,586.14 (-43.0%)
-141.41
est: 1,621.29 (-108.7%)
-2,970.54
est: 764.44 (-488.6%)
2,501.50
2,425.38 – 2,577.33
+227.2% YoY
3,468.00
2,108.44 – 4,827.56
+38.6% YoY
3,823.25
3,706.92 – 3,939.15
+10.2% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-28 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-27 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-26 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-22 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-21 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-20 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-19 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-18 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-15 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-14 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-13 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-12 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-11 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-08 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-05-07 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-05-06 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-05-04 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-04-30 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-04-29 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-28 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-27 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-24 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-23 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-22 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-21 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-20 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-17 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-16 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
55.84B
OE per share TTM
5,343.22
Owner's Yield
14.47%
Maintenance CapEx ratio
100.44%
Maint CapEx / Avg PPE
62.9%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 29 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Kodex Healthcare 266420.KS 0.15% 69.3K 0.09%
2 Kodex KOSPI 226490.KS 0.01% 94.7K 0.15%
3 Vanguard FTSE All-World ex-US Small-Cap ETF VSS 0.00% 601.1K 0.06%
4 Avantis Emerging Markets Small Cap Equity ETF AVEE 0.00% 4.0K 0.42%
5 Dimensional - Emerging Markets ex China Core Equity ETF DEXC 0.00% 8.6K 0.56%
6 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 155.5K 0.39%
7 Dimensional - Emerging Core Equity Market ETF DFAE 0.00% 124.0K 0.29%
8 Vanguard FTSE Developed All Cap ex North America Index ETF VIU.TO 0.00% 97.5K 0.23%
9 Vanguard FTSE Developed All Cap ex North America Index ETF (CAD-hedged) VI.TO 0.00% 8.4K 0.22%
10 Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO 0.00% 2.5K 0.22%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
366.5K
Shares Outstanding
9.64M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
SunJong So Managing Director 1B —
Yu-Seok Shin Managing Director 1B —
GyuHong Jo Managing Director 1B —
Jae-Hong Park President & Director 919M —
SeongAe Yoon Head 677M —
Jae-Hun Jung Chief Executive Officer, President & Director — —
DaeWoo Lee Executive Director — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic